Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion type Assertion NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_head.
- NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion description "[To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_provenance.
- NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion evidence source_evidence_literature NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_provenance.
- NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion SIO_000772 22562248 NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_provenance.
- NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion wasDerivedFrom befree-20150227 NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_provenance.
- NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_assertion wasGeneratedBy ECO_0000203 NP535992.RAm6C9cPtwy-vzNbUAe-Uyc0IAwZCLPsNwYUdWX4clqJY130_provenance.